Palisade Bio, Inc. (NASDAQ:PALI) Financings
Financings
| Raise | Date |
|---|---|
| Strategic investment of equity Announced: up to US$500,000 Buyers: Crohn’s & Colitis Foundation (IBD Ventures program) (strategic equity investment of up to $500,000) Use of proceeds: Continued clinical and mechanistic development of PALI-2108 for fibrostenotic Crohn's disease and ulcerative colitis | Jan 7, 2026 |
| Public offering of common stock (or common stock equivalents) Closed: US$138M raised · US$0.7 a share · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Buyers: B Group Capital (led the offering); Columbia Threadneedle Investments (led the offering); Adage Capital Partners LP (significant participation); ADAR1 Capital Management (significant participation); Boxer Capital Management (significant participation); Coastlands Capital (significant participation); Deep Track Capital (significant participation); Janus Henderson Investors (significant participation); Octagon Capital (significant participation); Perceptive Advisors (significant participation); RA Capital Management (significant participation); Squadron Capital Management (significant participation) Use of proceeds: To support the upcoming Phase 2 clinical development program for PALI-2108 in ulcerative colitis | Oct 2, 2025 |
| Warrant exercise of existing warrants to purchase common stock Announced: about US$3.9M · US$0.9047 a share · Warrants at US$0.9047 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes | Jul 24, 2025 |
| Public offering of class A Units and Class B Units (common stock or prefunded warrants with common warrants) Announced: about US$5M · US$1.525 a unit · Warrants at US$1.4 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital | Dec 12, 2024 |